Finance

Lists
BOI:EPA
Boiron USA
19,25 €
+0,52%
(+0,10) 1D
11 ნოე, 17:35:09 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BOI...
Open
19,15 €
High
19,40 €
Low
19,05 €
Mkt. cap
337,75 მლნ.
Avg. vol.
5,06 ათ.
Volume
2,02 ათ.
P/E ratio
12,76
52-wk high
32,25 €
52-wk low
16,90 €
EPS
1,51 €
Shares outstanding
17,55 მლნ.
No. of employees
3 ათ.
Open
19,15 €
High
19,40 €
Low
19,05 €
Mkt. cap
337,75 მლნ.
Avg. vol.
5,06 ათ.
Volume
2,02 ათ.
P/E ratio
12,76
52-wk high
32,25 €
52-wk low
16,90 €
EPS
1,51 €
Shares outstanding
17,55 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Profile
Boiron is a manufacturer of homeopathic products, headquartered in France and with an operating presence in 59 countries worldwide. It is the largest manufacturer of homeopathic products in the world. In 2004, it had a workforce of 2,779 and turnover of € 313 million. It is a member of the CAC Small stock index. In June 2005, the firm acquired Dolisos Laboratories, then the world's second largest manufacturer of homeopathic preparations. Products of Boiron include mono- and poly-preparations, which Boiron refer to as "proprietary drugs". Homeopathy is a pseudoscience with no evidence of effectiveness for stated claims or plausible mechanism of medicinal effect, and several class action lawsuits have been filed on behalf of consumers claiming that Boiron's homeopathic products, including Children's Coldcalm and Oscillococcinum, are useless and Boiron's marketing of these products is deceptive. Wikipedia
About Boiron USA
CEO-
Employees2,62 ათ.
Founded7 ივნ. 1932
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteboiron.fr
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
127,73 მლნ.
127,73 მლნ.
120,16 მლნ.
120,16 მლნ.
Cost of goods sold
35,40 მლნ.
35,40 მლნ.
33,53 მლნ.
33,53 მლნ.
Cost of revenue
35,40 მლნ.
35,40 მლნ.
33,53 მლნ.
33,53 მლნ.
Research and development expenses
1,56 მლნ.
1,56 მლნ.
1,44 მლნ.
1,44 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
79,26 მლნ.
79,26 მლნ.
79,95 მლნ.
79,95 მლნ.
Operating expense
77,52 მლნ.
77,52 მლნ.
81,88 მლნ.
81,88 მლნ.
Total operating expenses
112,92 მლნ.
112,92 მლნ.
115,41 მლნ.
115,41 მლნ.
Operating income
14,81 მლნ.
14,81 მლნ.
4,76 მლნ.
4,76 მლნ.
Other non operating income
-1,13 მლნ.
-1,13 მლნ.
-2,29 მლნ.
-2,29 მლნ.
EBT including unusual items
13,82 მლნ.
13,82 მლნ.
4,02 მლნ.
4,02 მლნ.
EBT excluding unusual items
13,16 მლნ.
13,16 მლნ.
2,75 მლნ.
2,75 მლნ.
Income tax expense
3,18 მლნ.
3,18 მლნ.
1,56 მლნ.
1,56 მლნ.
Effective tax rate
22,99%
22,99%
38,90%
38,90%
Other operating expenses
-3,30 მლნ.
-3,30 მლნ.
488,00 ათ.
488,00 ათ.
Net income
10,64 მლნ.
10,64 მლნ.
2,46 მლნ.
2,46 მლნ.
Net profit margin
8,33%
8,33%
2,04%
2,04%
Earnings per share
-
-
-
-
Interest and investment income
653,00 ათ.
653,00 ათ.
636,50 ათ.
636,50 ათ.
Interest expense
-335,00 ათ.
-335,00 ათ.
-410,00 ათ.
-410,00 ათ.
Net interest expenses
318,00 ათ.
318,00 ათ.
226,50 ათ.
226,50 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
18,06 მლნ.
18,06 მლნ.
11,17 მლნ.
11,17 მლნ.
Gain or loss from assets sale
-446,00 ათ.
-446,00 ათ.
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები